Data-centric software provider archTIS Ltd has secured a contract for its Trusted Data Integration (TDI) platform with a Japan-based company, marking its first sale in the region and the first commercialisation of its recently acquired Direktiv technology.
This initial Japanese market entry proves the strategic value of the acquisition, with the annual licence agreement valued at A$390,000.
Cadoux Ltd has added $686,761 to the war chest after receiving a research and development (R&D) tax incentive offset payment for expenditure related to the Minhub mineral sands and rare earth processing project (MSP) in Darwin, Northern Territory.
CCM is the 50% owner of Minihub Operations Pty Ltd (MOPL), which is developing the MSP with funding from Cadoux.
Race Oncology Ltd will soon begin a Phase 1 trial for RC220 in combination with doxorubicin after the Human Research Ethics Committee (HREC) approved the trial to begin at the Gosford and Wyong Hospitals within the Central Coast Local Health District in Australia.
Subject to final site approvals and activations, the two hospitals will begin enrolling patients during the month of April.
Analysts at Wedbush have boosted their price target on GameStop Corp (NYSE:GME) after the video game retailer unveiled the pricing of its offering of $1.3 billion convertible senior notes.
The company said the conversion rate to the notes will initially be 33.4970 shares of Class A common stock per $1,000 principal amount of such notes.
Hillcrest Energy Technologies Ltd (CSE:HEAT, OTCQB:HLRTF) announced that it has initiated a technology evaluation project with a global Tier 1 automotive supplier to assess its Zero Voltage Switching (ZVS) technology for next-generation electric vehicle inverters.
The first phase of the project will focus on evaluating the potential benefits of Hillcrest's ZVS technology in the supplier’s inverter applications, the company said.
OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules.
The biopharmaceutical company’s confirmation that urcosimod remains stable for over two and a half years in single-use ampoules – small, sealed containers designed to hold a single dose of liquid medication – is an important step in bringing the company closer to submitting a successful New Drug Application (NDA) for FDA approval.
Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) market value presents an opportunity according to stockbroker Cavendish – which, with a 1,800p price target, pencils in some 95% upside potential.
The Zimbabwe-based miner today released annual results that Cavendish analyst Will Dymott described as ‘in line with our expectations’, and confirmed that it had made a strong start to 2025.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is starting to find its feet again, with broker Cavdenidsh noting the 'financial recovery continues' with its analysis of first-half results.
The immunology specialist posted interim results on Monday showing revenue of £34 million for the six months to 31 December. That’s up just 1% on the same period a year earlier - or 4% if you strip out currency swings - but it’s the second half-year in a row that sales have grown.
Gaming Realms PLC (AIM:GMR, OTCQX:PSDMF) shares rose 5% in morning trading after the company reported a strong start to 2025 and confirmed it is trading in line with expectations.
The mobile gaming content developer said revenue from its core licensing business is up 22% so far this year, driven by new launches in Brazil and the US.
Shares in CRISM Therapeutics rose 18% in early trading after the company received positive feedback from the UK regulator on its planned clinical trial for ChemoSeed, a targeted chemotherapy treatment for high grade glioma.
The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that CRISM will not need to carry out additional preclinical toxicology studies, cutting an estimated £400,000 from development costs and speeding up the path to human trials.
Shares in Zinnwald Lithium PLC (LSE:ZNWD, OTC:ZNWLF) rose 12.5% in early trading on Monday after the company published a pre-feasibility study confirming the robust economics of its German lithium project.
The study values the integrated mining and processing operation at €2.2 billion post-tax, with the potential to generate €12.1 billion in free cash flow over a 41-year mine life. Initial production is expected to reach 18,000 tonnes of lithium hydroxide per year, doubling to 35,100 tonnes in a second phase.
Gaming Realms PLC (AIM:GMR, OTCQX:PSDMF) said it is on track for another strong year, with early 2025 trading in line with expectations and new launches already underway in Brazil and other key markets.
It said it expects continued growth as it expands into regulated markets, including South Africa and British Columbia in Canada later this year.
Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) described 2024 as ‘a year of significant progress’, financially and operationally, as it reported record annual results.
Operating cash flow totalled $42 million, from $14.8 million, on 76,656 ounces of gold production.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) expects sales growth to pick up in the second half of the year and has reiterated plans to launch its new grass pollen vaccine, Grass MATA MPL once it secures regulatory approval in Germany.
If greenlit by the Paul-Ehrlich-Institut (PEI), the short-course hay fever treatment could be on the market by this time next year, analysts reckon.
Adriatic Metals PLC (LSE:ADT1, ASX:ADT, OTCQX:ADMLF) reported a record quarter for processing at its Vareš Silver mine in Bosnia and Herzegovina, with 68,000 tonnes of ore milled in the first quarter, up 43% on the preceding three months.
Production for the period reached 1.3 million ounces of silver equivalent, up from 0.9 million ounces in the fourth quarter of 2024.
Itaconix PLC (AIM:ITX, OTCQB:ITXXF) has entered 2025 on a firm footing, saying it now has a more profitable client base and is trading in line with expectations following a year of reshaping the business.
The company, which makes plant-based polymers used in things like detergents, toothpaste and skincare, said it deliberately moved away from a major low-margin contract in North America.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) told investors it has now received a final payment of US$2.2 million from Burgundy Xploration LLC, due under the farm-out at Project Phoenix, in Alaska.
This payment follows a US$1 million instalment made in February and takes the explorer’s cash position to over A$10 million, the company noted.
Active Energy Group PLC (AIM:AEG, OTCQB:ATGVF), the renewable energy company focused on biomass, has had its European patent application approved for a process that cleans and upgrades biomass material.
The patent supports the company’s CoalSwitch technology, a cleaner, high-performance alternative to traditional biomass fuel. Once granted, the patent will apply across multiple EU countries, giving Active Energy broader protection for its process.
Futura Medical PLC (AIM:FUM, OTC:FAMDF), the company behind the sexual health product Eroxon, has just added a new face to its board. Harmesh Suniara has joined as a non-executive director, starting straight away.
Suniara brings more than 17 years of experience in investment management, particularly with UK small and mid-cap companies.
Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) told investors it has now formally accepted the offer of a Mining Licence for its southern Rukwa Helium Project in Tanzania, marking an important milestone for the project.
The Rukwa licence covers 480 square kilometres in the southern Rukwa Basin – and alongside the licence, the company also has been issued an Environmental and Social Impact Assessment and it has paid the first annual licence fee.